Since alterations in TDP-43 have been found in 97% of ALS cases and about 50% of FTD cases (Ling et al., 2013), the reduction of ataxin-2 could be used as therapeutic strategy for ALS and FTD treatment (Wils et al., 2010). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.